Chemycal has been acquired by 3E
Learn MoreDiscover how Chemycal PRO helps you boosting your regulatory monitoring:
Documents prepared following evaluation of the additional information submitted by the applicant in accordance with Commission Implementing Regulation 2018/1659 to address the approval criteria on endocrine disruption set out in point 3.6.5 and/or point 3.8.2 of Annex II to Regulation (EC) No 1107/2009, and/or to demonstrate that Metiram may be used such that exposure is negligible, or as regards the application of the derogation under Art.4(7) of Regulation (EC) No 1107/2009
CONTINUE READING ON www.efsa.europa.eu
2013 © MyChemicalMonitoring. ALL Rights Reserved. About Us | Terms and Conditions